Vice President, Chemistry, deCODE chemistry
David oversees the work of deCODE chemistry's medicinal chemistry and chemical development operations. He directs all personnel working within chemistry services. David is also responsible for overseeing the business development operations within deCODE chemistry including directing our business development associates as well as helping to facilitate and maintain client relationships. David earned his B.S. in Chemistry from University of Central Florida in 1986 and his Ph.D. in Organic Chemistry from Georgia Institute of Technology in 1990. He completed his postdoctoral fellowship at the Mayo Clinic in 1995 and went on to earn his M.B.A. from Kellogg Graduate School of Management (Northwestern University) in 2001. David came to deCODE chemistry in February 1995, then known as Medichem as a Senior Research Scientist. He established the Combinatorial Chemistry division in 1996 and served as the Director of Combinatorial Chemistry through March 2000. David has been awarded 6 SBIR grants from the National Institutes of Health focused on the discovery and pre-clinical development of antiviral and anticancer agents. He has authored or co- authored 18 papers published in peer-reviewed scientific journals, and is an inventor on 11 issued U.S. patents.
Back to top
Jasbir Singh, Ph.D.
Vice President, Medicinal Chemistry, deCODE chemistry
Prior to joining deCODE chemistry, Jasbir was Director of Medicinal Chemistry for Cephalon, Inc. from 1996 through 2001. Jasbir is a renowned medicinal chemist with over twenty years of pharmaceutical experience in the design, synthesis and development of novel therapeutic agents. He has demonstrated success in advancing several programs from discovery to development in multidisciplinary settings. Jasbir works with senior management at deCODE chemistry to define program goals which meet the scientific and business needs of the organization and its customers, and coordinates timelines and priorities for various therapeutic groups. Within deCODE chemistry, Jasbir has been responsible for overseeing the development of medicinal chemistry services and maintaining the quality and innovation of deCODE chemistry's research. Examples of Jasbir's leadership include the rapid progression of two tyrosine kinase-based inhibitor programs from lead discovery to pre-development status, each in two years, and invention of a novel "kinase chemotype". Jasbir held various leadership roles for Sterling Winthrop Pharmaceuticals from 1981 to 1994. He received his Ph.D. in medicinal chemistry from the University of Wisconsin at Madison, and he received both his M.S. in Organic Chemistry and B.S. in Chemistry from the University of Delhi in India. Jasbir has published 39 papers and is the inventor on 18 issued U.S. patents.
Back to top
Frank Muellner, Ph.D.
Director, Process Chemistry, deCODE chemistry
Frank provides scientific leadership and project management through oversight of the process chemistry group and the chemical development programs at deCODE chemistry. He has over 17 years of pharmaceutical process development experience. Frank earned both his B.S. in Pharmacy and his Ph.D. in Medicinal Chemistry at the University of Illinois at Chicago. He completed his postdoctoral fellowship at the University of Chicago in 1988. Prior to coming to deCODE chemistry Frank spent over 15 years with Monsanto/Searle/Pharmacia/Pfizer where he led technical teams as Project Team Leader and Process Validation Team Leader. Frank has led cross-functional Active Pharmaceutical Ingredient (API) Project Teams from discovery through launch, including production of API materials, development and validation of commercial API processes, facilitation of their transfer, and implementation at manufacturing sites.
Back to top
Director of Quality Assurance, deCODE chemistry
Cara has almost 20 years of experience in pharmaceutical development. She began her career with Searle in 1985 which became Pfizer in 2003. In her position as Associate Director of Analytical Development with Pfizer she led a cross-functional team of Q.A., R&D, and manufacturing professionals in designing global systems for developing, validating, and monitoring analytical methods. She played an important role in the approval of the key products Celebrex® and Bextra® through preparation of CMC documentation and involvement in PAI inspections. Cara came to deCODE chemistry in February 2004. She currently heads the quality assurance group within deCODE chemistry and is responsible for monitoring all GLP and GMP compliance as well as overseeing all regulatory documentation within the organization. She has played a leading role in advancing deCODE chemistry's quality systems and works with its clients to ensure compliance in their outsourced programs. She earned her Bachelors degree in Chemistry from Ripon College in 1985 and her M.B.A. from Keller Graduate School of Management in 1992.
Back to top
Jenny Lin, M.S.
Director of Analytical Chemistry, deCODE chemistry
Jenny joined MediChem (now deCODE chemistry) in 1994. She has served as Director of Analytical Chemistry since 1998. She established deCODE chemistry's analytical services department. Analytical services that Jenny oversees include method development and validation, stability studies, reference standard certification, impurity characterization, large-scale separation, biological molecular analysis, and GLP/GMP product releases. She has been author or co-author on 6 papers published in peer-reviewed scientific journals, along with 8 oral and poster presentations. Jenny is an inventor on 7 issued U.S. patents. Jenny earned her B.S. in Analytical Chemistry from Beijing University in 1989, and her M.S. in Medicinal Chemistry from University of Connecticut in 1994.
Back to top
Mitchell B. Friedman, PhD DABT
Director, Drug Safety & Metabolism, deCODE chemistry
Mitch comes to deCODE with over 25 years of experience in the pharmaceutical industry. He spent the bulk of his career in Abbott Laboratories' Pharmaceutical Products Division heading up the department of toxicology where he provided both drug discovery and drug development support. In addition, Mitch served as one of the U.S. representatives on the international working group that developed the ICH guidelines for medical devices, and was one of the original members of the safety committee of the International Pharmaceutical Excipients Council. He has extensive experience with both domestic and international regulatory authorities ranging from preparation of INDs, NDAs and Expert Reports. Mitch and his team provide the integration of formulation, safety, pharmacokinetics and metabolism for both drug discovery and development. He received his B.S. in biology and chemistry from the University of Kansas and his PhD in pharmacology and toxicology from the University of Texas at Austin. He is board certified by the American Board of Toxicology.
Back to top